CHIs combined with EGFR-TKIs improved the expression of CD3+ and CD4+ T cells, as well as the CD4+/CD8+ ratio, implying that CHIs exert their anti-tumor activity by augmenting human immune function. The gene discussed is CD8A; the disease is neoplasm.